Three Products of MicroPort® Included in 2016 Shanghai Innovative Product Recommendation List

Shanghai, China – Three products in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") - Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Columbus® 3D EP Navigation System ("Columbus®") and WILLIS® Intracranial Stent Graft System ("WILLIS®") – were included in the Category of High-performance Medical Device of the 2016 Shanghai Innovative Product Recommendation List ("Recommendation List") according to an announcement recently released by Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality and Shanghai Zhangjiang High-tech Industrial Development Zone Management Committee.
The Recommendation List is designed to facilitate the implantation of Shanghai government's strategies to build a technological innovation center in the city, to promote the industry upgrading, companies' innovation and the commercialization of innovative products, as well as to cultivate new technologies, new businesses, news models and new industries. The Recommendation List is expected to provide references to decision makers of government purchasing, enterprise purchasing, funding allocation and investment and financing institutions.
Firehawk® is the world's first and only target eluting stent ("TES"), and is the world's lowest drug dosage stent. It adopts unique in-groove abluminal coating design and target-eluting technique, which allow Firehawk® to achieve the same clinical efficacy with significantly low drug loading. Columbus®, which provides information about the electrical activity of the heart and catheter location in real time with magnetic location, is designed for the diagnosis of arrhythmias and acts as guidance for catheter ablation. WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China. It is also the first medical device to achieve complete vascular reconstruction in China.
The three products are innovations of many years' in-house research and development of MicroPort® and its subsidiaries. As they have been counted in the Recommendation List, it once again demonstrated MicroPort®'s sustainable innovation abilities. In the future, MicroPort® will continue to carry forward its unique innovation mode and build a market-oriented technology innovation system integrating enterprises, universities and research institutes for enhancing independent innovation, integrated innovation and cooperative innovation, so as to produce more products of independent intellectual property, strengthen MicroPort®'s overall competiveness, and drive the development of China's high-end medical device industry.